{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:25:15Z","timestamp":1771489515160,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autosomal dominant optic atrophy (DOA) is an inherited optic neuropathy that results in progressive, bilateral visual acuity loss\u00a0and field defects. <jats:italic>OPA1<\/jats:italic> is the causative gene in around 60% of cases of DOA. The majority of patients have a pure ocular phenotype, but 20% have extra-ocular features (DOA\u2009+). We report on a patient with DOA\u2009+\u2009manifesting as bilateral optic atrophy, spastic paraparesis, urinary incontinence and white matter changes in the central nervous system associated with a novel heterozygous splice variant NM_015560.2(<jats:italic>OPA1<\/jats:italic>):c.2356-1\u2009G\u2009&gt;\u2009T. Further characterisation, which was performed using fibroblasts obtained from a skin biopsy, demonstrated that this variant altered mRNA splicing of the <jats:italic>OPA1<\/jats:italic> transcript, specifically a 21 base pair deletion at the start of exon 24, NM_015560.2(<jats:italic>OPA1<\/jats:italic>):p.Cys786_Lys792del. The majority of variant transcripts were shown to escape nonsense-mediated\u00a0decay and modelling of the predicted protein structure suggests that the in-frame 7 amino acid deletion may affect OPA1 oligomerisation. Fibroblasts carrying the c.2356-1\u2009G\u2009&gt;\u2009T variant demonstrated impaired mitochondrial bioenergetics, membrane potential, increased cell death, and disrupted and fragmented mitochondrial networks in comparison to WT cells. This study suggests that the c.2356-1\u2009G\u2009&gt;\u2009T <jats:italic>OPA1<\/jats:italic> splice site variant leads to a cryptic splice site activation and may manifest in a dominant-negative manner, which could account for the patient\u2019s severe syndromic phenotype.<\/jats:p>","DOI":"10.1038\/s41431-022-01102-0","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T08:04:04Z","timestamp":1652083444000},"page":"848-855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characterisation of a novel OPA1 splice variant resulting in cryptic splice site activation and mitochondrial dysfunction"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5581-9596","authenticated-orcid":false,"given":"Joshua Paul","family":"Harvey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7847-9320","authenticated-orcid":false,"given":"Patrick","family":"Yu-Wai-Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Edward","family":"Cheetham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"1102_CR1","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.ophtha.2009.12.038","volume":"117","author":"P Yu-Wai-Man","year":"2010","unstructured":"Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L, et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology 2010;117:1538\u201346. 1546.e1","journal-title":"Ophthalmology"},{"key":"1102_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jmg.2007.054270","volume":"46","author":"P Yu-Wai-Man","year":"2008","unstructured":"Yu-Wai-Man P, Griffiths P, Hudson G, Chinnery P. Inherited mitochondrial optic neuropathies. J Med Genet. 2008;46:145\u201358.","journal-title":"J Med Genet"},{"key":"1102_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/brain\/awq007","volume":"133","author":"P Yu-Wai-Man","year":"2010","unstructured":"Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010;133:771\u201386.","journal-title":"Brain"},{"key":"1102_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41431-018-0235-y","volume":"27","author":"N Jurkute","year":"2019","unstructured":"Jurkute N, Majander A, Bowman R, Votruba M, Abbs S, Acheson J, et al. Clinical utility gene card for: inherited optic neuropathies including next-generation sequencing-based approaches. Eur J Hum Genet. 2019;27:494.","journal-title":"Eur J Hum Genet"},{"key":"1102_CR5","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1093\/brain\/awu165","volume":"137","author":"T Bonifert","year":"2014","unstructured":"Bonifert T, Karle K, Tonagel F, Batra M, Wilhelm C, Theurer B, et al. Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier. Brain 2014;137:2164\u201377.","journal-title":"Brain"},{"key":"1102_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jmedgenet-2015-103361","volume":"53","author":"R Spiegel","year":"2016","unstructured":"Spiegel R, Saada A, Flannery PJ, Burt\u00e9 F, Soiferman D, Khayat M, et al. Fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy associated with a homozygous OPA1 mutation. J Med Genet. 2016;53:127\u201331.","journal-title":"J Med Genet"},{"key":"1102_CR7","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/hmg\/ddm079","volume":"16","author":"VJ Davies","year":"2007","unstructured":"Davies VJ, Hollins AJ, Piechota MJ, Yip W, Davies JR, White KE, et al. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet. 2007;16:1307\u201318.","journal-title":"Hum Mol Genet"},{"key":"1102_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/brain\/awm005","volume":"130","author":"MV Alavi","year":"2007","unstructured":"Alavi MV, Bette S, Schimpf S, Schuettauf F, Schraermeyer HF, Wehrl MVA, et al. A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain 2007;130:1029\u201342.","journal-title":"Brain"},{"key":"1102_CR9","doi-asserted-by":"crossref","unstructured":"Lenaers G, Hamel C, Delettre C, Amati-Bonneau P, Procaccio V, Bonneau D, et al. Dominant optic atrophy. Orphanet J Rare Dis. 2012;7:46.","DOI":"10.1186\/1750-1172-7-46"},{"key":"1102_CR10","doi-asserted-by":"publisher","first-page":"e0253987","DOI":"10.1371\/journal.pone.0253987","volume":"16","author":"N Weisschuh","year":"2021","unstructured":"Weisschuh N, Schimpf-Linzenbold S, Mazzola P, Kieninger S, Xiao T, Kellner U, et al. Mutation spectrum of the OPA1 gene in a large cohort of patients with suspected dominant optic atrophy: Identification and classification of 48 novel variants. PLoS One. 2021;16:e0253987.","journal-title":"PLoS One"},{"key":"1102_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3109\/13816810.2015.1066829","volume":"37","author":"K Lida","year":"2016","unstructured":"Lida K, Ohkuma K, Hayashi T, Katagiri S, Fujita T, Tsunoda K, et al. A novel heterozygous splice site OPA1 mutation causes exon 10 skipping in Japanese patients with dominant optic atrophy. Ophthalmic Genet. 2016;37:354\u20136.","journal-title":"Ophthalmic Genet"},{"key":"1102_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12881-017-0383-x","volume":"18","author":"R Bolognini","year":"2017","unstructured":"Bolognini R, Gerth-Kahlert C, Abegg M, Bartholdi D, Mathis N, Sturm V, et al. Characterization of two novel intronic OPA1 mutations resulting in aberrant pre-mRNA splicing. BMC Med Genet. 2017;18:1\u20139.","journal-title":"BMC Med Genet"},{"key":"1102_CR13","doi-asserted-by":"publisher","unstructured":"Sun C, Wu X, Bai H-X, Wang C, Liu Z, Yang C, et al. OPA1 haploinsufficiency due to a novel splicing variant resulting in mitochondrial dysfunction without mitochondrial DNA depletion. 2020;42:45\u201352. https:\/\/doi.org\/10.1080\/13816810.2020.1849313.","DOI":"10.1080\/13816810.2020.1849313"},{"key":"1102_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/acn3.323","volume":"3","author":"P Yu\u2010Wai\u2010Man","year":"2016","unstructured":"Yu\u2010Wai\u2010Man P, Spyropoulos A, Duncan HJ, Guadagno JV, Chinnery PF. A multiple sclerosis\u2010like disorder in patients with OPA1 mutations. Ann Clin Transl Neurol. 2016;3:723.","journal-title":"Ann Clin Transl Neurol"},{"key":"1102_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/1066527041410418","volume":"11","author":"G Yeo","year":"2004","unstructured":"Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol. 2004;11:377\u201394.","journal-title":"J Comput Biol"},{"key":"1102_CR16","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/nar\/gkp215","volume":"37","author":"FO Desmet","year":"2009","unstructured":"Desmet FO, Hamroun D, Lalande M, Collod-B\u00ebroud G, Claustres M, B\u00e9roud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009;37:e67\u2013e67.","journal-title":"Nucleic Acids Res"},{"key":"1102_CR17","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1093\/nar\/gkl535","volume":"34","author":"I Vo\u0159echovsk\u00fd","year":"2006","unstructured":"Vo\u0159echovsk\u00fd I. Aberrant 3\u2019 splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res. 2006;34:4630\u201341.","journal-title":"Nucleic Acids Res"},{"key":"1102_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0022-2836(91)90380-O","volume":"220","author":"S Brunak","year":"1991","unstructured":"Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol. 1991;220:49\u201365.","journal-title":"J Mol Biol"},{"key":"1102_CR19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nprot.2015.053","volume":"10","author":"LA Kelley","year":"2015","unstructured":"Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. 2015;10:845\u201358.","journal-title":"Nat Protoc"},{"key":"1102_CR20","unstructured":"Corporation P. Wizard(R) Genomic DNA Purification Kit Technical Manual #TM050 [Internet]. https:\/\/www.promega.co.uk\/resources\/protocols\/technical-manuals\/0\/wizard-genomic-dna-purification-kit-protocol\/."},{"key":"1102_CR21","unstructured":"RNeasy Mini Handbook - (EN) - QIAGEN [Internet]. https:\/\/www.qiagen.com\/gb\/resources\/resourcedetail?id=14e7cf6e-521a-4cf7-8cbc-bf9f6fa33e24&lang=en."},{"key":"1102_CR22","unstructured":"TetroTM cDNA Synthesis Kit [Internet] https:\/\/www.bioline.com\/tetro-cdna-synthesis-kit.html."},{"key":"1102_CR23","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/nprot.2006.273","volume":"1","author":"B Cox","year":"2006","unstructured":"Cox B, Emili A. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat Protoc. 2006;1:1872\u20138.","journal-title":"Nat Protoc"},{"key":"1102_CR24","unstructured":"LDH Assay Kit (Cytotoxicity) (ab65393) | Abcam [Internet]. https:\/\/www.abcam.com\/ldh-assay-kit-cytotoxicity-ab65393.html."},{"key":"1102_CR25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.omtn.2021.08.015","volume":"26","author":"PE Sladen","year":"2021","unstructured":"Sladen PE, Perdig\u00e3o PRL, Salsbury G, Novoselova T, van der Spuy J, Chapple JP, et al. CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs. Mol Ther - Nucleic Acids 2021;26:432\u201343.","journal-title":"Mol Ther - Nucleic Acids"},{"key":"1102_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"B Le Roux","year":"2019","unstructured":"Le Roux B, Lenaers G, Zanlonghi X, Amati-Bonneau P, Chabrun F, Foulonneau T, et al. OPA1: 516 unique variants and 831 patients registered in an updated centralized Variome database. Orphanet J Rare Dis. 2019;14:1\u20139.","journal-title":"Orphanet J Rare Dis"},{"key":"1102_CR27","doi-asserted-by":"crossref","unstructured":"Yu-Wai-Man P, Trenell MI, Hollingsworth KG, Griffiths PG, Chinnery PF. OPA1 mutations impair mitochondrial function in both pure and complicated dominant optic atrophy [Internet]. Vol. 134, Brain. Oxford University Press; 2011. p. e164.","DOI":"10.1093\/brain\/awq288"},{"key":"1102_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/brain\/awm298","volume":"131","author":"P Amati-Bonneau","year":"2008","unstructured":"Amati-Bonneau P, Valentino ML, Reynier P, Gallardo M, Bornstein B, Boissi\u00e8re A, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy \u201cplus\u201d phenotypes. Brain 2008;131:338\u201351.","journal-title":"Brain"},{"key":"1102_CR29","doi-asserted-by":"crossref","unstructured":"Barboni P, Savini G, Cascavilla M, Caporali L, Milesi J, Borrelli E, et al. Early macular retinal ganglion cell loss in dominant optic atrophy: genotype-phenotype correlation. Am J Ophthalmol. 2014;158:628\u201336.","DOI":"10.1016\/j.ajo.2014.05.034"},{"key":"1102_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s13353-018-0444-7","volume":"59","author":"A Anna","year":"2018","unstructured":"Anna A, Monika G. Splicing mutations in human genetic disorders: Examples, detection, and confirmation. J Appl Genet. 2018;59:253\u201368.","journal-title":"J Appl Genet"},{"key":"1102_CR31","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1167\/iovs.14-16288","volume":"56","author":"SH Kao","year":"2015","unstructured":"Kao SH, Yen MY, Wang AG, Yeh YL, Lin AL. Changes in mitochondrial morphology and bioenergetics in human lymphoblastoid cells with four novel OPA1 mutations. Invest Ophthalmol Vis Sci. 2015;56:2269\u201378.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1102_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1167\/iovs.61.6.42","volume":"61","author":"S Sun","year":"2020","unstructured":"Sun S, Erchova I, Sengpiel F, Votruba M. Opa1 Deficiency Leads to Diminished Mitochondrial Bioenergetics With Compensatory Increased Mitochondrial Motility. Invest Ophthalmol Vis Sci. 2020;61:42\u201342.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1102_CR33","doi-asserted-by":"crossref","unstructured":"Weisschuh N, Marino V, Sch\u00e4ferhoff K, Richter P, Park J, Haack TB, et al. Mutations at a split codon in the GTPase-encoding domain of OPA1 cause dominant optic atrophy through different molecular mechanisms. Hum Mol Genet. 2021;31:761\u201374.","DOI":"10.1093\/hmg\/ddab286"},{"key":"1102_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nsmb.1550","volume":"16","author":"S Brogna","year":"2009","unstructured":"Brogna S, Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat Struct Mol Biol. 2009;16:107\u201313.","journal-title":"Nat Struct Mol Biol"},{"key":"1102_CR35","doi-asserted-by":"crossref","unstructured":"Li D, Wang J, Jin Z, Zhang Z. Structural and evolutionary characteristics of dynamin-related GTPase OPA1. PeerJ. 2019;7:e7285.","DOI":"10.7717\/peerj.7285"},{"key":"1102_CR36","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/ncb0805-766","volume":"7","author":"B Meusser","year":"2005","unstructured":"Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol. 2005;7:766\u201372.","journal-title":"Nat Cell Biol"},{"key":"1102_CR37","first-page":"32","volume":"8","author":"MV Alavi","year":"2013","unstructured":"Alavi MV, Fuhrmann N. Dominant optic atrophy, OPA1, and mitochondrial quality control: Understanding mitochondrial network dynamics [Internet], Molecular Neurodegeneration. BioMed Cent. 2013;8:32.","journal-title":"BioMed Cent"},{"key":"1102_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrn2417","volume":"9","author":"AB Knott","year":"2008","unstructured":"Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci. 2008;9:505\u201318.","journal-title":"Nat Rev Neurosci"},{"key":"1102_CR39","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.15252\/embj.201488349","volume":"33","author":"DA Patten","year":"2014","unstructured":"Patten DA, Wong J, Khacho M, Soubannier V, Mailloux RJ, Pilon-Larose K, et al. OPA1-dependent cristae modulation is essential for cellular adaptation to metabolic demand. EMBO J. 2014;33:2676.","journal-title":"EMBO J"},{"key":"1102_CR40","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1091\/mbc.e09-03-0252","volume":"20","author":"Z Song","year":"2009","unstructured":"Song Z, Ghochani M, McCaffery JM, Frey TG, Chan DC. Mitofusins and OPA1 Mediate Sequential Steps in Mitochondrial Membrane Fusion. Mol Biol Cell. 2009;20:3525.","journal-title":"Mol Biol Cell"},{"key":"1102_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"J Zhang","year":"2017","unstructured":"Zhang J, Liu X, Liang X, Lu Y, Zhu L, Fu R, et al. A novel ADOA-associated OPA1 mutation alters the mitochondrial function, membrane potential, ROS production and apoptosis. Sci Rep. 2017;7:1\u201313.","journal-title":"Sci Rep"},{"key":"1102_CR42","doi-asserted-by":"crossref","unstructured":"Teti G, Focaroli S, Salvatore V, Mazzotti E, Ingra L, Mazzotti A, et al. The hypoxia-mimetic agent cobalt chloride differently affects human mesenchymal stem cells in their chondrogenic potential. Stem Cells Int. 2018;9.","DOI":"10.1155\/2018\/3237253"},{"key":"1102_CR43","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s00018-019-03024-5","volume":"76","author":"J Byrne","year":"2019","unstructured":"Byrne J, Soh M, Chandhok G, Vijayaraghavan T, Teoh J, Crawford S, et al. Disruption of mitochondrial dynamics affects behaviour and lifespan in Caenorhabditis elegans. Cell Mol Life Sci. 2019;76:1967\u201385.","journal-title":"Cell Mol Life Sci"},{"key":"1102_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1750-1326-8-32","volume":"8","author":"MV Alavi","year":"2013","unstructured":"Alavi MV, Fuhrmann N. Dominant optic atrophy, OPA1, and mitochondrial quality control: Understanding mitochondrial network dynamics. Mol Neurodegener. 2013;8:32.","journal-title":"Mol Neurodegener"},{"key":"1102_CR45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/bies.201400188","volume":"37","author":"H Hoitzing","year":"2015","unstructured":"Hoitzing H, Johnston IG, Jones NS. What is the function of mitochondrial networks? A theoretical assessment of hypotheses and proposal for future research. Bioessays 2015;37:687.","journal-title":"Bioessays"},{"key":"1102_CR46","unstructured":"Venkatesh A, Zhiyu L, Anne C, Kian Huat L, Jacob K, Robert H, et al. Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic. Invest. Ophthalmol. Vis. Sci. 2020;61:2755."}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01102-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01102-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01102-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T23:07:29Z","timestamp":1657148849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01102-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1038\/s41431-022-01102-0","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"4 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The collection and use of human tissues had the relevant ethical approval (NRES Committee, Yorkshire and The Humber \u2013 Leeds Bradford Research Ethics Committee (REC 13\/YH\/0310).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}